Inhibition of Th17 Cell Differentiation as a Treatment for Multiple Sclerosis

Abstract

The goal of this project is to develop miR-326 small molecule inhibitors (SMIs) for the treatment of Multiple Sclerosis (MS). Our global approach consists of creating stable transfectants with a luciferase reporter gene and 3 target sequence for miR-326. The addition of hsa-miR-326 (delivered either by lentivirus or cotransfection) results in reduced fluorescence, that can be restored by the addition of inhibitors of miR-326. Our efforts to develop a screening method for miR-326 were not successful therefore we were not able to screen compounds. Additionally, experiments aimed to reproduce data showing an association of miR-326 with Th17 cells failed to support that concept. We did not observe any up-regulation of miR326 in Th17 over other T cells.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2013
Accession Number
ADA589923

Entities

People

  • Annalisa D Andrea

Organizations

  • SRI International

Tags

DTIC Thesaurus Topics

  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Coding
  • Culture Techniques
  • Diseases And Disorders
  • Inhibition
  • Inhibitors
  • Luminescence
  • Lymphocytes
  • Molecules
  • Multiple Sclerosis
  • Sclerosis
  • Sequences
  • Small Molecules
  • Tumor Cell Line

Fields of Study

  • Biology

Readers

  • Aerospace Propulsion Engineering.
  • Molecular Biology and Genetics
  • Molecular Genetics